"Strong partnership! AB&B BIO-TECH-B (02627) joins hands with Walvax Biotechnology to start the new journey of exporting third-generation flu vaccines."

On March 13, AB&B BIO-TECH-B (02627) and Walvax Biotechnology (300142.SZ) officially signed a strategic cooperation agreement for overseas markets for influenza virus subunit vaccines in Taizhou. The two parties announced that they will jointly promote the independently developed influenza virus subunit vaccine by Zhonghui Bio out to sea. This is not only a milestone moment for the cooperation and construction of the health industry ecosystem by Chinese vaccine companies, but also marks China bringing safer and more effective solutions to the global influenza prevention and control field. Hardcore technology going overseas showcases China's innovative strength in vaccines According to the agreement, the core product going overseas this time is the influenza virus subunit vaccine (Hualin 3) independently developed by Zhonghui Bio. This product was approved for marketing in January 2026, and is the first and only trivalent influenza virus subunit vaccine in China suitable for the entire population aged 6 months and above. The two parties will carry out in-depth cooperation in the overseas market registration, sales, and commercialization of the product. In the wave of global influenza vaccine technological iterations, "Hualin 3" stands out with its third-generation influenza vaccine technology. It only extracts the core antigens on the surface of the virus (HA/NA), removes internal viral impurities, has higher purity, lower adverse reactions, better safety, and superior immunization effects. Phase III clinical data show lower local adverse reactions compared to the control group's split vaccine. A full dose can provide stronger immune protection for infants and young children, with good safety. Hualin 3 is groundbreaking in achieving a unified dose of 0.5ml for the entire population aged 6 months and above, allowing infants and adults to receive the same dose for protection, greatly simplifying the vaccination process and providing medical staff with a more convenient and efficient operational experience. In addition, Hualin 3 uses the VVM label (vaccine heat label) for intuitive judgment of vaccine effectiveness by medical staff and recipients, strengthening the last visual defense line for vaccine inoculations, making each vaccination more reassuring and worry-free. Strong cooperation to jointly create a new global market map In this cooperation, Zhonghui Bio will leverage Walvax Biotechnology's years of experience and mature channel network in overseas markets to accelerate the entry of the product into countries in Southeast Asia, Latin America, the Middle East, and the Southern Hemisphere. As a pioneer in strong overseas business growth in recent years, Walvax Biotechnology's rich international operational experience will give wings to Zhonghui Bio's innovative technology and product advantages to release greater potential on the global stage, truly realizing the vision of providing high-quality Chinese vaccines to the world. A responsible person from Zhonghui Bio stated, "The strategic cooperation with Walvax Biotechnology is a key move in the company's global layout. What we are exporting is not just a product, but also the quality standards and technical confidence of Chinese vaccines. With the high-end dual line of defense of 'quadrivalent + trivalent' vaccines, we are confident in flexibly meeting the diverse public health needs globally and bringing health protection to more families around the world." A responsible person from Walvax Biotechnology also pointed out, "Zhonghui Bio's products have significant differentiation advantages in technology and clinical value, which align well with Walvax Biotechnology's mission of 'sowing health, creating beauty'. We believe that the overseas launch of this high-end subunit vaccine will significantly enhance the brand image of Chinese vaccines in international markets and inject strong new momentum into the growth of both parties." Anchoring new growth poles to jointly build a global health defense line With the deepening of strategic cooperation, the overseas market will gradually open up, and the product advantages of Zhonghui Bio will deep synergize with the channel advantages of Walvax Biotechnology, injecting a continuous and surging momentum into the growth of both parties in the coming years. However, the value of this strategic cooperation goes far beyond the commercial win-win at the business level. It is a milestone, signaling that Chinese vaccine companies are moving from "going it alone" in the past to "ecosystem win-win" today, opening up a new chapter of collaborative overseas expansion in the Chinese vaccine industry. With this as a starting point, the two parties will work together to deepen their roots and resonate on the vast global stage of public health. Let high-quality vaccines originating from China become a solid barrier to safeguarding global health; let the wisdom and dedication of Chinese vaccine personnel inject a more majestic "Chinese power" into the construction of a global community of health for humanity.